Blueprint Medicines (BPMC)
(Real Time Quote from BATS)
$93.17 USD
+2.44 (2.69%)
Updated Apr 26, 2024 02:48 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for Blueprint Medicines Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 249 | 204 | 180 | 794 | 67 |
Cost Of Goods | 13 | 27 | 26 | 0 | 0 |
Gross Profit | 237 | 177 | 154 | 793 | 67 |
Selling & Adminstrative & Depr. & Amort Expenses | 723 | 715 | 796 | 485 | 428 |
Income After Depreciation & Amortization | -486 | -538 | -642 | 309 | -361 |
Non-Operating Income | -20 | -15 | 1 | 6 | 14 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -506 | -552 | -641 | 315 | -348 |
Income Taxes | 1 | 5 | 3 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -507 | -558 | -644 | 314 | -348 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -507 | -558 | -644 | 314 | -348 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -492 | -527 | -634 | 316 | -361 |
Depreciation & Amortization (Cash Flow) | -6 | 11 | 8 | 7 | 0 |
Income After Depreciation & Amortization | -486 | -538 | -642 | 309 | -361 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 60.56 | 59.64 | 58.52 | 56.17 | 47.83 |
Diluted EPS Before Non-Recurring Items | -8.37 | -9.35 | -6.60 | 5.59 | -7.27 |
Diluted Net EPS (GAAP) | -8.37 | -9.35 | -11.01 | 5.59 | -7.27 |
Fiscal Year end for Blueprint Medicines Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 71.96 | 56.57 | 57.57 | 63.29 |
Cost Of Goods | NA | 0.22 | 4.55 | 3.56 | 4.47 |
Gross Profit | NA | 71.74 | 52.01 | 54.01 | 58.82 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 176.85 | 180.99 | 181.99 | 183.02 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -105.11 | -128.98 | -127.98 | -124.20 |
Non-Operating Income | NA | -9.56 | -0.73 | -4.62 | -4.83 |
Interest Expense | NA | -3.81 | 3.81 | 0.00 | 0.00 |
Pretax Income | NA | -110.86 | -133.52 | -132.60 | -129.04 |
Income Taxes | NA | 0.06 | 0.20 | 0.19 | 0.52 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -110.92 | -133.71 | -132.79 | -129.56 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -110.92 | -133.71 | -132.79 | -129.56 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 60.89 | 60.69 | 60.52 | 60.13 |
Diluted EPS Before Non-Recurring Items | NA | -1.82 | -2.20 | -2.19 | -2.15 |
Diluted Net EPS (GAAP) | NA | -1.83 | -2.20 | -2.19 | -2.15 |